BIO ENGINEERED STENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Bio-engineered stents consist of short narrow metal or plastic tube, which is used to treat blocked arteries. It is used by patients who are suffering from different types of cardiovascular diseases such as coronary heart disease and ischemic heart disease. Different types of bio-engineered stent are available in market for various diseases such as coronary artery disease, peripheral arterial disease, carotid artery disease, renal artery stenosis, abdominal aortic aneurysm, thoracic aortic aneurysm among others.

Market Dynamics

Increasing prevalence of renal diseases is a major factor driving bio-engineered stents market growth. According to American Heart Association Council, in 2015, cardiovascular disease was the leading cause of death worldwide, accounting for over 17.9 million deaths annually and this number is expected to increase to over 23.6 million by 2030. According to the same source, cardiovascular diseases accounted for around 836,546 deaths in the U.S. in 2015, which accounted for around 1 in every 3 deaths.

Moreover, key players in the market are focused on adopting various strategies such as new Product Type launch and approvals and partnerships and collaborations to increase their foothold in the market. For instance, in May 2017, Medtronic plc., received the U.S. Food and Drug Administration (FDA) approval and Resolute Onyx, 4.5 MM and 5 mm sizes Drug-Eluting Stent. This device has proven clinical performance and superior deliverability of the Resolute Integrity. This device is intended to treat people with coronary artery disease in the U.S.

However, availability of alternatives for the treatment of cardiac diseases, Product Type recalls and failure, and stringent regulations for Product Type approvals are expected to hinder the market growth. For instance in November 2017, Abbott recall Class 1 Device Recall Absorb Bioresorbable Vascular Scaffold (BVS) System, an absorbable coronary drug-eluting stent due to elevated rates of major adverse events, specifically, myocardial infraction and scaffold thrombosis when compared to patients treated with the Xience metallic drug eluting stent.

Key features of the study

• This report provides in-depth analysis of the bio-engineered stents market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
• It profiles key players in the global bio-engineered stents market based on the following parameters – company overview, financial performance, Product Type portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include, Medtronic, plc., Boston Scientific Corporation, Abbott Laboratories, Biotronik SE & Co. KG, B. Braun Melsungen AG, Terumo Corporation, MicroPort Scientific Corporation, Stentys Sao, Meril Life Sciences Pvt. Ltd, Vascular Concepts, W. L. Gore and Associates, C. R. Bard, Endologix, Inc., Lombard Medical Technologies, Translumina GmbH, and Jotec GmbH
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global Bio-engineered stents market report caters to various stakeholders in this industry including investors, suppliers, Product Type manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the bio-engineered stents market

Market Segmentation

• By Application Type
  • Coronary artery disease
  • Peripheral arterial disease
  • Carotid Artery Disease
  • Renal Artery Stenosis
  • Abdominal Aortic Aneurysm
  • Thoracic Aortic Aneurysm
  • Others
• By Product Type
  • Drug-eluting Stents
  • Bioabsorbable Stents
  • Drug-eluting balloons
• By Mode of Delivery
  • Balloon-expandable Stents
  • Self-expanding Stents
• By Material Type
  • Metal-based
  • Polymer-based
• By End User
  • Hospitals & Cardiac Centers
  • Ambulatory Surgical Centers
  • Others
• By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC Countries
    • Israel
    • Rest of Middle East & Africa
• Key Players
  • Medtronic, plc.
  • Boston Scientific Corporation
  • Abbott Laboratories
  • Biotronik SE & Co. KG
  • Braun Melsungen AG
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • Stentys Sao
  • Meril Life Sciences Pvt. Ltd
  • Vascular Concepts
  • L. Gore and Associates
  • R. Bard
  • Endologix, Inc.
  • Lombard Medical Technologies
  • Translumina GmbH
  • JOTEC GmbH